Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency

OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of endocrinology 2000-09, Vol.143 (3), p.397-403
Hauptverfasser: Weintrob, N, Brautbar, C, Pertzelan, A, Josefsberg, Z, Dickerman, Z, Kauschansky, A, Lilos, P, Peled, D, Phillip, M, Israel, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 403
container_issue 3
container_start_page 397
container_title European journal of endocrinology
container_volume 143
creator Weintrob, N
Brautbar, C
Pertzelan, A
Josefsberg, Z
Dickerman, Z
Kauschansky, A
Lilos, P
Peled, D
Phillip, M
Israel, S
description OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed in 45 unrelated Israeli Jewish patients (nine males) with NC21-OHD (60min 17-hydroxyprogesterone (17-OHP), 45-386nmol/l) who were referred for evaluation of postnatal virilization or true precocious/early puberty. Eleven siblings diagnosed through family screening were genotyped as well. METHODS: Patients were divided by genotype into three groups: (A) homozygous or compound heterozygous for the mild mutations (V281L or P30L) (n=29; eight males); (B) compound heterozygous for one mild and one severe mutation (Q318X, I2 splice, I172N) (n=12; no males); (C) mild mutation detected on one allele only (n=4; one male; peak 17-OHP 58-151nmol/l). We then related the genotype to the ethnic origin, clinical phenotype and hormone level. Since group C was very small, comparisons were made between groups A and B only. RESULTS: At diagnosis, group B tended to be younger (5. 8+/-3.0 vs 8.1+/-4.3 years, P=0.09), had greater height SDS adjusted for mid-parental height SDS (1.6+/-1.1 vs 0.7+/-1.4, P=0.034), tended to have more advanced bone age SDS (2.9+/-1.5 vs 1.7+/-2.1, P=0.10) and had a higher peak 17-OHP level in response to ACTH stimulation (226+/-92 vs 126+/-62nmol/l, P
doi_str_mv 10.1530/eje.0.1430397
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72321256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72321256</sourcerecordid><originalsourceid>FETCH-LOGICAL-b449t-d46c74f6b8289ddf29e74673c6a7bced26cc3e1eeb0c6c64978a64b42782b1443</originalsourceid><addsrcrecordid>eNpFkN9LwzAQx4Mobk4ffZUK4ltmfi1JH2XoFAaCKPhW0vTKMrqmNh3Y_96UFn26L3cf7o4PQteULOmKkwfYwzJGwQlP1QmaU6FSLDX_OkVzoonAQgo-Qxch7AmhMZNzNKOUMEY1n6P3DdS-6xvAzW5KiQnBW2c65-uQuDqpfY1tFbvOmioJHbTeFQmjeNcXrf_p4wiSAkpnHdS2v0RnpakCXE11gT6fnz7WL3j7tnldP25xLkTa4UJIq0Qpc810WhQlS0EJqbiVRuUWCiat5UABcmKllSJV2kiRC6Y0y6kQfIHux71N67-PELrs4IKFqjI1-GPIFOOMspWMIB5B2_oQWiizpnUH0_YZJdkgMYsSsxhHiZG_mRYf8wMU__RkLQJ3E2BCVFK2prYu_HNCU50OD96OWO58GNx0Ljoyf9xw6xc9IIcn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72321256</pqid></control><display><type>article</type><title>Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Weintrob, N ; Brautbar, C ; Pertzelan, A ; Josefsberg, Z ; Dickerman, Z ; Kauschansky, A ; Lilos, P ; Peled, D ; Phillip, M ; Israel, S</creator><creatorcontrib>Weintrob, N ; Brautbar, C ; Pertzelan, A ; Josefsberg, Z ; Dickerman, Z ; Kauschansky, A ; Lilos, P ; Peled, D ; Phillip, M ; Israel, S</creatorcontrib><description>OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed in 45 unrelated Israeli Jewish patients (nine males) with NC21-OHD (60min 17-hydroxyprogesterone (17-OHP), 45-386nmol/l) who were referred for evaluation of postnatal virilization or true precocious/early puberty. Eleven siblings diagnosed through family screening were genotyped as well. METHODS: Patients were divided by genotype into three groups: (A) homozygous or compound heterozygous for the mild mutations (V281L or P30L) (n=29; eight males); (B) compound heterozygous for one mild and one severe mutation (Q318X, I2 splice, I172N) (n=12; no males); (C) mild mutation detected on one allele only (n=4; one male; peak 17-OHP 58-151nmol/l). We then related the genotype to the ethnic origin, clinical phenotype and hormone level. Since group C was very small, comparisons were made between groups A and B only. RESULTS: At diagnosis, group B tended to be younger (5. 8+/-3.0 vs 8.1+/-4.3 years, P=0.09), had greater height SDS adjusted for mid-parental height SDS (1.6+/-1.1 vs 0.7+/-1.4, P=0.034), tended to have more advanced bone age SDS (2.9+/-1.5 vs 1.7+/-2.1, P=0.10) and had a higher peak 17-OHP level in response to ACTH stimulation (226+/-92 vs 126+/-62nmol/l, P&lt;0.01). Group B also had pubarche and gonadarche at an earlier age (5.1+/-2.4 vs 7.4+/-2.2 years, P&lt;0.01 and 7.4+/-1.8 vs 9.9+/-1.4 years, P&lt;0.001, respectively) and a higher rate of precocious puberty (50 vs 17%, P=0.04). Stepwise logistic regression analysis (excluding males) yielded age at gonadarche as the most significant variable differentiating the two groups, with a positive predictive value of 86% for a cut-off of 7.5 years. CONCLUSIONS: The findings suggest that genotype might explain some of the variability in the phenotypic expression of NC21-OHD. Compound heterozygotes for one mild and one severe mutation have a higher peak 17-OHP associated with pubarche and gonadarche at an earlier age and more frequent precocious puberty. Hence, the severity of the enzymatic defect might determine the timing and pattern of puberty.</description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1530/eje.0.1430397</identifier><identifier>PMID: 11022183</identifier><language>eng</language><publisher>Colchester: European Society of Endocrinology</publisher><subject>17-alpha-Hydroxyprogesterone - blood ; Adolescent ; Adrenal Hyperplasia, Congenital ; Alleles ; Anti-Inflammatory Agents - therapeutic use ; Biological and medical sciences ; Body Height ; Child ; Child, Preschool ; Female ; Genotype ; Gonadotropin-Releasing Hormone - agonists ; Gynecology. Andrology. Obstetrics ; Humans ; Hydrocortisone - blood ; Hydrocortisone - therapeutic use ; Infant ; Infant, Newborn ; Male ; Medical sciences ; Mutation ; Phenotype ; Puberal and climacteric disorders (male and female) ; Steroid 21-Hydroxylase - genetics ; Tropical medicine</subject><ispartof>European journal of endocrinology, 2000-09, Vol.143 (3), p.397-403</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b449t-d46c74f6b8289ddf29e74673c6a7bced26cc3e1eeb0c6c64978a64b42782b1443</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1481894$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11022183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weintrob, N</creatorcontrib><creatorcontrib>Brautbar, C</creatorcontrib><creatorcontrib>Pertzelan, A</creatorcontrib><creatorcontrib>Josefsberg, Z</creatorcontrib><creatorcontrib>Dickerman, Z</creatorcontrib><creatorcontrib>Kauschansky, A</creatorcontrib><creatorcontrib>Lilos, P</creatorcontrib><creatorcontrib>Peled, D</creatorcontrib><creatorcontrib>Phillip, M</creatorcontrib><creatorcontrib>Israel, S</creatorcontrib><title>Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description>OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed in 45 unrelated Israeli Jewish patients (nine males) with NC21-OHD (60min 17-hydroxyprogesterone (17-OHP), 45-386nmol/l) who were referred for evaluation of postnatal virilization or true precocious/early puberty. Eleven siblings diagnosed through family screening were genotyped as well. METHODS: Patients were divided by genotype into three groups: (A) homozygous or compound heterozygous for the mild mutations (V281L or P30L) (n=29; eight males); (B) compound heterozygous for one mild and one severe mutation (Q318X, I2 splice, I172N) (n=12; no males); (C) mild mutation detected on one allele only (n=4; one male; peak 17-OHP 58-151nmol/l). We then related the genotype to the ethnic origin, clinical phenotype and hormone level. Since group C was very small, comparisons were made between groups A and B only. RESULTS: At diagnosis, group B tended to be younger (5. 8+/-3.0 vs 8.1+/-4.3 years, P=0.09), had greater height SDS adjusted for mid-parental height SDS (1.6+/-1.1 vs 0.7+/-1.4, P=0.034), tended to have more advanced bone age SDS (2.9+/-1.5 vs 1.7+/-2.1, P=0.10) and had a higher peak 17-OHP level in response to ACTH stimulation (226+/-92 vs 126+/-62nmol/l, P&lt;0.01). Group B also had pubarche and gonadarche at an earlier age (5.1+/-2.4 vs 7.4+/-2.2 years, P&lt;0.01 and 7.4+/-1.8 vs 9.9+/-1.4 years, P&lt;0.001, respectively) and a higher rate of precocious puberty (50 vs 17%, P=0.04). Stepwise logistic regression analysis (excluding males) yielded age at gonadarche as the most significant variable differentiating the two groups, with a positive predictive value of 86% for a cut-off of 7.5 years. CONCLUSIONS: The findings suggest that genotype might explain some of the variability in the phenotypic expression of NC21-OHD. Compound heterozygotes for one mild and one severe mutation have a higher peak 17-OHP associated with pubarche and gonadarche at an earlier age and more frequent precocious puberty. Hence, the severity of the enzymatic defect might determine the timing and pattern of puberty.</description><subject>17-alpha-Hydroxyprogesterone - blood</subject><subject>Adolescent</subject><subject>Adrenal Hyperplasia, Congenital</subject><subject>Alleles</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body Height</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Genotype</subject><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Hydrocortisone - therapeutic use</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Phenotype</subject><subject>Puberal and climacteric disorders (male and female)</subject><subject>Steroid 21-Hydroxylase - genetics</subject><subject>Tropical medicine</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkN9LwzAQx4Mobk4ffZUK4ltmfi1JH2XoFAaCKPhW0vTKMrqmNh3Y_96UFn26L3cf7o4PQteULOmKkwfYwzJGwQlP1QmaU6FSLDX_OkVzoonAQgo-Qxch7AmhMZNzNKOUMEY1n6P3DdS-6xvAzW5KiQnBW2c65-uQuDqpfY1tFbvOmioJHbTeFQmjeNcXrf_p4wiSAkpnHdS2v0RnpakCXE11gT6fnz7WL3j7tnldP25xLkTa4UJIq0Qpc810WhQlS0EJqbiVRuUWCiat5UABcmKllSJV2kiRC6Y0y6kQfIHux71N67-PELrs4IKFqjI1-GPIFOOMspWMIB5B2_oQWiizpnUH0_YZJdkgMYsSsxhHiZG_mRYf8wMU__RkLQJ3E2BCVFK2prYu_HNCU50OD96OWO58GNx0Ljoyf9xw6xc9IIcn</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Weintrob, N</creator><creator>Brautbar, C</creator><creator>Pertzelan, A</creator><creator>Josefsberg, Z</creator><creator>Dickerman, Z</creator><creator>Kauschansky, A</creator><creator>Lilos, P</creator><creator>Peled, D</creator><creator>Phillip, M</creator><creator>Israel, S</creator><general>European Society of Endocrinology</general><general>Portland Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency</title><author>Weintrob, N ; Brautbar, C ; Pertzelan, A ; Josefsberg, Z ; Dickerman, Z ; Kauschansky, A ; Lilos, P ; Peled, D ; Phillip, M ; Israel, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b449t-d46c74f6b8289ddf29e74673c6a7bced26cc3e1eeb0c6c64978a64b42782b1443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>17-alpha-Hydroxyprogesterone - blood</topic><topic>Adolescent</topic><topic>Adrenal Hyperplasia, Congenital</topic><topic>Alleles</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body Height</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Genotype</topic><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Hydrocortisone - therapeutic use</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Phenotype</topic><topic>Puberal and climacteric disorders (male and female)</topic><topic>Steroid 21-Hydroxylase - genetics</topic><topic>Tropical medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weintrob, N</creatorcontrib><creatorcontrib>Brautbar, C</creatorcontrib><creatorcontrib>Pertzelan, A</creatorcontrib><creatorcontrib>Josefsberg, Z</creatorcontrib><creatorcontrib>Dickerman, Z</creatorcontrib><creatorcontrib>Kauschansky, A</creatorcontrib><creatorcontrib>Lilos, P</creatorcontrib><creatorcontrib>Peled, D</creatorcontrib><creatorcontrib>Phillip, M</creatorcontrib><creatorcontrib>Israel, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weintrob, N</au><au>Brautbar, C</au><au>Pertzelan, A</au><au>Josefsberg, Z</au><au>Dickerman, Z</au><au>Kauschansky, A</au><au>Lilos, P</au><au>Peled, D</au><au>Phillip, M</au><au>Israel, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>143</volume><issue>3</issue><spage>397</spage><epage>403</epage><pages>397-403</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract>OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed in 45 unrelated Israeli Jewish patients (nine males) with NC21-OHD (60min 17-hydroxyprogesterone (17-OHP), 45-386nmol/l) who were referred for evaluation of postnatal virilization or true precocious/early puberty. Eleven siblings diagnosed through family screening were genotyped as well. METHODS: Patients were divided by genotype into three groups: (A) homozygous or compound heterozygous for the mild mutations (V281L or P30L) (n=29; eight males); (B) compound heterozygous for one mild and one severe mutation (Q318X, I2 splice, I172N) (n=12; no males); (C) mild mutation detected on one allele only (n=4; one male; peak 17-OHP 58-151nmol/l). We then related the genotype to the ethnic origin, clinical phenotype and hormone level. Since group C was very small, comparisons were made between groups A and B only. RESULTS: At diagnosis, group B tended to be younger (5. 8+/-3.0 vs 8.1+/-4.3 years, P=0.09), had greater height SDS adjusted for mid-parental height SDS (1.6+/-1.1 vs 0.7+/-1.4, P=0.034), tended to have more advanced bone age SDS (2.9+/-1.5 vs 1.7+/-2.1, P=0.10) and had a higher peak 17-OHP level in response to ACTH stimulation (226+/-92 vs 126+/-62nmol/l, P&lt;0.01). Group B also had pubarche and gonadarche at an earlier age (5.1+/-2.4 vs 7.4+/-2.2 years, P&lt;0.01 and 7.4+/-1.8 vs 9.9+/-1.4 years, P&lt;0.001, respectively) and a higher rate of precocious puberty (50 vs 17%, P=0.04). Stepwise logistic regression analysis (excluding males) yielded age at gonadarche as the most significant variable differentiating the two groups, with a positive predictive value of 86% for a cut-off of 7.5 years. CONCLUSIONS: The findings suggest that genotype might explain some of the variability in the phenotypic expression of NC21-OHD. Compound heterozygotes for one mild and one severe mutation have a higher peak 17-OHP associated with pubarche and gonadarche at an earlier age and more frequent precocious puberty. Hence, the severity of the enzymatic defect might determine the timing and pattern of puberty.</abstract><cop>Colchester</cop><pub>European Society of Endocrinology</pub><pmid>11022183</pmid><doi>10.1530/eje.0.1430397</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0804-4643
ispartof European journal of endocrinology, 2000-09, Vol.143 (3), p.397-403
issn 0804-4643
1479-683X
language eng
recordid cdi_proquest_miscellaneous_72321256
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects 17-alpha-Hydroxyprogesterone - blood
Adolescent
Adrenal Hyperplasia, Congenital
Alleles
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
Body Height
Child
Child, Preschool
Female
Genotype
Gonadotropin-Releasing Hormone - agonists
Gynecology. Andrology. Obstetrics
Humans
Hydrocortisone - blood
Hydrocortisone - therapeutic use
Infant
Infant, Newborn
Male
Medical sciences
Mutation
Phenotype
Puberal and climacteric disorders (male and female)
Steroid 21-Hydroxylase - genetics
Tropical medicine
title Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A00%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genotype-phenotype%20associations%20in%20non-classical%20steroid%2021-hydroxylase%20deficiency&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=Weintrob,%20N&rft.date=2000-09-01&rft.volume=143&rft.issue=3&rft.spage=397&rft.epage=403&rft.pages=397-403&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1530/eje.0.1430397&rft_dat=%3Cproquest_cross%3E72321256%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72321256&rft_id=info:pmid/11022183&rfr_iscdi=true